Latest News

  • John Nosta: The brilliant mind that never stopped questioning

    Remembering a pioneering thinker whose journey from cardiovascular science to artificial intelligence challenged how we understand innovation, cognition and the human experience. The world of health innovation has lost one of its most original and provocative thinkers. John Nosta, scientist, strategist, author and influential voice in artificial intelligence and human cognition, has died following an [...]

  • Heidi cuts 18% of staff as two co-founders depart

    Heidi is cutting about 18 per cent of its global workforce as two co-founders prepare to leave, six weeks after announcing an A$475m funding package. The Melbourne-based AI healthcare company, which develops technology to automatically generate clinical notes, is restructuring its operations despite reporting continued growth. Co-founder and chief executive Dr Thomas Kelly informed employees [...]

  • Laza Medical raises US$160m for AI imaging tech

    Laza Medical has raised up to US$160m in Series B financing as it develops AI-powered robotic imaging technology for cardiac procedures. The California-based medical technology company is developing a system to provide real-time views of the heart and guide clinicians during procedures in cardiac catheterisation laboratories, commonly known as cath labs. Its flagship product, the [...]

  • 8.4 million people in England take five or more medicines: Genetics explains part of what goes wrong

    Posted in partnership with Spital Clinic Pharmacogenomic testing has been available, affordable and recommended for years without becoming routine. It is also a smaller part of the overprescribing problem than its advocates imply. The scale is set out in the Department of Health and Social Care’s National Overprescribing Review, summarised by the NHS Specialist Pharmacy [...]

  • 1nhaler raises £2.2m to take cardboard inhaler towards clinical testing

    1nhaler has secured £2.2m in follow-on funding to advance its cardboard inhaler towards clinical testing and a regulatory filing targeted for late 2027. The Edinburgh-based medical device company will use the investment for late-stage development of 1nhaler Salbutamol, which combines its single-dose dry powder inhaler with the established asthma medicine salbutamol. The funding will support [...]

  • From patient care to billing: What hospitals really need from an EHR

    Health Tech World Q&A with Baha Zeidan, founder and chief strategy officer, Azalea Health 1. East Adams Rural Health, a critical access rural hospital in Ritzville, Washington that provides a wide range of healthcare services, determined that a large enterprise EHR wasn’t the right fit for its organisation. What should rural healthcare providers consider when [...]

  • Alethio Therapeutics secures £67m for blood cancer treatments

    Alethio Therapeutics has raised US$90m (£67m) to advance its experimental treatment for the blood cancer essential thrombocythaemia towards clinical trials. The Oxford-based biotechnology company will use the Series A funding to progress its lead drug candidate, ATX-011, through planned Phase 1/2a studies and towards Phase 3 readiness. The investment will also support additional programmes for [...]

  • Cooling device to helps reduce chemotherapy nerve damage

    Paxman has launched a cooling device designed to reduce the risk and severity of chemotherapy-related nerve damage, expanding beyond scalp cooling. The Paxman Neuropathy System combines cooling and compression, known as cryocompression, to help prevent chemotherapy-induced peripheral neuropathy (CIPN), a common side effect of cancer treatment. CIPN can cause numbness, pain, tingling and loss of [...]

  • JawBuddy raises €818,000 for jaw pain app

    JawBuddy has raised €818k in pre-seed funding to support a clinical trial of its jaw pain app and seek reimbursement from German health insurers. The Leipzig-based health technology company has developed a digital platform offering personalised exercises to help manage jaw pain, teeth grinding and tension affecting the temporomandibular joint (TMJ). The funding will support [...]

  • APIS and BIOTYPE partner to commercialise cancer testing kits

    APIS Assay Technologies and BIOTYPE have announced a commercial partnership to bring two molecular testing kits to market, targeting treatment resistance in breast cancer and genetic factors linked to chemotherapy toxicity. BIOTYPE will commercialise the tests under its ExaccType brand, expanding its portfolio in oncology and pharmacogenetics, which examines how genetic differences affect responses to [...]